Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2206291 | 1.00 | HPGD (0.51) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL19291614 | 0.99 | NR1H4 (0.49) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL11996359 | 0.88 | ACACB (0.52) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL4568749 | 0.86 | HPGD (0.51) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL4568756 | 0.86 | HPGD (0.51) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL25825857 | 0.86 | HPGD (0.46) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL25818233 | 0.86 | HPGD (0.46) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL29818710 | 0.85 | KAT6A (0.53) | KAT6ANR1H4SIRT2PARP15PARP10 | |
| SCHEMBL4568983 | 0.85 | NR1H4 (0.49) | HPGDRAB9ASMN1; SMN2KAT6AADAM17 | |
| SCHEMBL2208791 | 0.85 | KAT6A (0.53) | KAT6ANR1H4SIRT2PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | HPGD 110/4885RAB9A 2078/4885SMN1; SMN2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.